Press Release: GlucoModicum publishes for the first time human data to assess the |

GlucoModicum released First–in–human data Assessing the safety and effectiveness of it is BBD technology to the accurate needle-free glucose monitoring

• Human data shows a high correlation between glucose concentration in samples extracted with MHD technology and capillary blood glucose samples with a MARD of 12.9%
• Subsequent post-study improvements have resulted in <9% MARD.
• The results further validate MHD for accurate, needle-free continuous glucose monitoring
• Significant advances in Talisman product development with Philips-Medisize, a global leader in MedTech design and development

Helsinki, Finland, 09 November 2022 – GlucoModicum, a company transforming glucose monitoring with precise, needle-free magnetohydrodynamic (MHD) technology, announces that it has published peer-reviewed data from the first human study evaluating the safety and efficacy of its proprietary MHD needle-free measurement technology of glucose levels was published in Scientific ReportsPart of…